|
|
|
|
UPDATE 4-Sanofi wins FDA approval for heart drug Multaq
PARIS, July 2 (Reuters) - Sanofi-Aventis won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly offset a looming sales drop as generics to several key drugs appear.Analysts...
|
|
|
UPDATE 4-Sanofi wins FDA approval for heart drug Multaq
PARIS, July 2 (Reuters) - Sanofi-Aventis ( SNY - news - people ) won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly offset a looming sales drop as generics to several key...
|
|
|
UPDATE 4-Sanofi wins FDA approval for heart drug Multaq
* U.S.FDA clears Multaq for atrial fibrillation, flutter * Sanofi says plans commercial launch this summer * Boxed warning not to use in cases of severe heart failure * Shares close 1.9 percent lower as European shares fall (Adds FDA...
|
|
|
UPDATE 4-Sanofi wins FDA approval for heart drug Multaq
PARIS, July 2 (Reuters) - Sanofi-Aventis won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly offset a looming sales drop as generics to several key drugs appear.Analysts...
|
|
|
Sanofi wins FDA approval for heart drug
Sanofi-Aventis won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly recoup a future sales drop as generics to several key drugs appear.Analysts see Multaq, put forward as a...
|
|
|
F.D.A. Approves Sanofi Heart Treatment
PARIS (Reuters) The drug maker Sanofi-Aventis won approval to sell heart treatment Multaq in the United States, a move that should help the company partly recoup a future sales drop as generics to several crucial drugs appear.Analysts see...
|
|
|
UPDATE 3-Sanofi wins FDA approval for Multaq heart drug
PARIS, July 2 (Reuters) - Sanofi-Aventis won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly recoup a future sales drop as generics to several key drugs appear.Analysts see...
|
|
|
UPDATE 3-Sanofi wins FDA approval for Multaq heart drug
PARIS, July 2 (Reuters) - Sanofi-Aventis ( SNY - news - people ) won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly recoup a future sales drop as generics to several key...
|
|
|
UPDATE 3-Sanofi wins FDA approval for Multaq heart drug
* U.S.FDA clears Multaq for atrial fibrillation, flutter * Sanofi says plans commercial launch this summer * Multaq not for patients with severe heart failure * Sanofi shares up as much as 1.7 pct, outperform peers (Adds background on...
|
|
|
UPDATE 3-Sanofi wins FDA approval for Multaq heart drug
PARIS, July 2 (Reuters) - Sanofi-Aventis won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly recoup a future sales drop as generics to several key drugs appear.Analysts see...
|
|
|
RPT-UPDATE 2-Sanofi wins FDA approval for Multaq heart drug
PARIS, July 2 (Reuters) - Sanofi-Aventis ( SNY - news - people ) won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly recoup a future sales drop as generics to several key...
|
|
|
UPDATE 2-Sanofi wins FDA approval for Multaq heart drug
PARIS, July 2 (Reuters) - Sanofi-Aventis ( SNY - news - people ) won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly recoup a future sales drop as generics to several key...
|
|
|
RPT-UPDATE 2-Sanofi wins FDA approval for Multaq heart drug
* U.S.FDA clears Multaq for atrial fibrillation, flutter * Sanofi says plans commercial launch this summer * Multaq not for patients with severe heart failure * Sanofi shares up as much as 1.7 pct, outperform peers (Adds detail,...
|
|
|
RPT-UPDATE 2-Sanofi wins FDA approval for Multaq heart drug
* U.S.FDA clears Multaq for atrial fibrillation, flutter * Sanofi says plans commercial launch this summer * Multaq not for patients with severe heart failure * Sanofi shares up as much as 1.7 pct, outperform peers (Adds detail,...
|
|
|
RPT-UPDATE 2-Sanofi wins FDA approval for Multaq heart drug
PARIS, July 2 (Reuters) - Sanofi-Aventis won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly recoup a future sales drop as generics to several key drugs appear.Analysts see...
|
|
|
UPDATE 2-Sanofi wins FDA approval for Multaq heart drug
PARIS, July 2 (Reuters) - Sanofi-Aventis won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly recoup a future sales drop as generics to several key drugs appear.Analysts see...
|
|
|
UPDATE 2-Sanofi wins FDA approval for Multaq heart drug
* U.S.FDA clears Multaq for atrial fibrillation, flutter * Sanofi says plans commercial launch this summer * Multaq not for patients with severe heart failure * Sanofi shares up as much as 1.7 pct, outperform peers (Adds detail,...
|
|
|
Drug-eluting stents make a comeback
Introduced in 2003, drug-eluting stents (DES) represented the third revolution in interventional cardiology, after balloon angioplasty and bare-metal stents.Boston Scientific's paclitaxel-eluting Taxus stent achieved more sales in its...
|
|
|
US FDA questions cancer link with Sanofi's Lantus
* FDA says studies may be too short to assess risk * Questions whether cancer risk 'truly exists' * Sanofi shares up 3.1 percent NEW YORK/WASHINGTON (Reuters) - The U.S.Food and Drug Administration on Wednesday cast doubt on recent...
|
|
|
FDA plays down cancer link with Sanofi's Lantus (Reuters)
Play Video Cancer Video:Obama Hugs Cancer Patient During Forum ABC News Play Video Cancer Video:Obama hugs emotional cancer patient at town hall AP Play Video Cancer Video:The serious side of Cameron Diaz AP By Lewis Krauskopf and Susan...
|
|
|
Drugmaker Sanofi -Aventis to close some research labs
TRENTON, New Jersey (AP) - French drugmaker Sanofi-Aventis SA on Tuesday announced a major corporate restructuring on the heels of new safety concerns that could hurt sales of a key drug, its once-a-day insulin Lantus.The world's third...
|
|
|
Sanofi-Aventis to close some plants, restructure
French drugmaker Sanofi-Aventis SA on Tuesday announced a major corporate restructuring on the heels of new safety concerns that could hurt sales of a key drug, its once-a-day insulin Lantus.The world's third-largest pharmaceutical firm...
|
|
|
UPDATE 3-US FDA plays down cancer link with Sanofi's Lantus
NEW YORK/WASHINGTON, July 1 (Reuters) - The U.S.Food and Drug Administration on Wednesday cast doubt on recent studies that suggested possible cancer risk with Sanofi-Aventis ( SNY - news - people )' widely used Lantus diabetes drug,...
|
|
|
Drug-eluting stents make a comeback
Introduced in 2003, drug-eluting stents (DES) represented the third revolution in interventional cardiology, after balloon angioplasty and bare-metal stents.Boston Scientific's paclitaxel-eluting Taxus stent achieved more sales in its...
|
|
|
UPDATE 3-US FDA plays down cancer link with Sanofi's Lantus
By Lewis Krauskopf and Susan Heavey NEW YORK/WASHINGTON, July 1 (Reuters) - The U.S.Food and Drug Administration on Wednesday cast doubt on recent studies that suggested possible cancer risk with Sanofi-Aventis' widely used Lantus...
|
